Related Experiment Video
Updated: Jul 6, 2026
11:48
Detection of Alternative Splicing During Epithelial-Mesenchymal Transition
Published on: October 9, 2014
MESOMARK kit detects C-ERC/mesothelin, but not SMRP with C-terminus
Tatsuya Segawa1, Yoshiaki Hagiwara, Kiyoshi Ishikawa
1Immuno-Biological Laboratories Co. Ltd., 5-1 Aramachi, Takasaki, Gunma 370-0831, Japan.
Biochemical and Biophysical Research Communications
|March 11, 2008
Summary
Researchers investigated soluble mesothelin-related peptide (SMRP) as a diagnostic marker for mesothelioma. Their enzyme-linked immunosorbent assay (ELISA) found no evidence of SMRP in patient serum, questioning its utility.
Area of Science:
- Oncology
- Biochemistry
- Molecular Biology
Background:
- ERC/mesothelin is expressed in normal mesothelium and cancers like mesothelioma and ovarian carcinoma.
- A splicing isoform, SMRP, was proposed as a diagnostic marker for mesothelioma due to its soluble C-terminus.
- The presence of SMRP in mesothelioma patient serum remained unconfirmed.
Purpose of the Study:
- To establish a novel enzyme-linked immunosorbent assay (ELISA) system for detecting SMRP.
- To investigate the existence of SMRP in the serum of mesothelioma patients.
Main Methods:
- Development of a new ELISA system specifically designed for SMRP detection.
- Analysis of mesothelioma patient serum samples using the established ELISA system.
Main Results:
- The developed ELISA system detected both N- and C-ERC/mesothelin in mesothelioma patient serum.
- Crucially, SMRP was not detected in any of the analyzed serum samples.
- Results suggest that the SMRP detected by the MESOMARK kit lacks a soluble C-terminus and is indistinguishable from C-ERC/mesothelin.
Conclusions:
- The study failed to demonstrate the existence of SMRP in mesothelioma patient serum.
- The findings challenge the utility of SMRP as a standalone diagnostic marker for mesothelioma.
- Further research is required to clarify the relationship between SMRP and mesothelin in mesothelioma.
